AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33705355
Drug: 1,000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,000 IU daily vitamin D3 supplementation
Trial: 33705355
Drug: 3,000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3,000 IU daily vitamin D3 supplementation
Trial: 36396999
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg L-1 SiO2-NPs
Trial: 36396999
Drug: SiO2-NPs treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SiO2-NPs treatment
Trial: 34811384
Drug: Weekly interactive
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly interactive text messages asking 'How are you?' until 24 months postpartum.
Trial: 32559503
Drug: Covariates (treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Covariates (treatment group, time, baseline depression severity)
Trial: 32729275
Drug: Drug-coated balloon
RxNorm normalized name: CATHETER,BALLOON
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-coated balloon angioplasty (DBA)
Trial: 32966683
Drug: 60 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 g/d of mixed nuts (nut group)
Trial: 32210455
Drug: EMLA cream
RxNorm normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMLA cream (1 g, 25 mg lidocaine + 25 mg prilocaine applied 1 hour prior to puncture)
Trial: 32210455
Drug: Lidocaine tape
RxNorm normalized name: lidocaine Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine tape (one sheet, 18 mg lidocaine applied 30 minutes prior to puncture)
Trial: 36210311
Drug: Thoracodorsal flap
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thoracodorsal flap and implant
Trial: 32213342
Drug: Subcutaneous daratumumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous daratumumab (1800 mg co-formulated with 2000 U/mL recombinant human hyaluronidase PH20)
Trial: 32213342
Drug: Intravenous daratumumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous daratumumab (16 mg/kg)
Trial: 38832105
Drug: Subcutaneous daratumumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous daratumumab
Trial: 32213342
Drug: Intravenous daratumumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous daratumumab
Trial: 32070386
Drug: Initial treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial treatment planning
Trial: 36399909
Drug: Induction therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction therapy (six cycles of 5‐fluorouracil, leucovorin [FU/FA], oxaliplatin [FOLFOX] and panitumumab [Pmab])
Trial: 36399909
Drug: Maintenance therapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance therapy (FU/FA plus Pmab)
Trial: 36399909
Drug: Maintenance therapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance therapy (FU/FA alone)
Trial: 33148693
Drug: Nivolumab and
RxNorm normalized name: nivolumab and relatlimab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab and ipilimumab combination therapy
Trial: 35452458
Drug: Low-dose remifentanil
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose remifentanil (0.25 mcg/kg/min)
Trial: 35452458
Drug: High-dose remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose remifentanil (0.5 mcg/kg/min)
Trial: 35452458
Drug: Remifentanil (combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil (combined dosage)
Trial: 32229597
Drug: Intensive therapy
RxNorm normalized name: Cortaid Intensive Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive therapy (n = 4,755)
Trial: 32229597
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (n = 4,728)
Trial: 36165878
Drug: Naloxone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (10 mg hidden injection)
Trial: 36165878
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution (hidden injection)
Trial: 33962579
Drug: PSMA PET/CT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSMA PET/CT prior to definitive radiation therapy (dRT)
Trial: 32260313
Drug: Monopolar dielectric
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Monopolar dielectric radiofrequency (MDR) treatment (8 sessions of 20 minutes each)
Trial: 32260313
Drug: Sham MDR
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sham MDR therapy (8 sessions of 20 minutes each)
Trial: 35726109
Drug: eMBCT (web-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eMBCT (web-based mindfulness-based cognitive therapy)
Trial: 32871616
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron (IVI)
Trial: 32871616
Drug: Oral iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral iron (OI)
Trial: 34504409
Drug: Controlled treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled treatments (no biochar)
Trial: 35312188
Drug: Linear multilevel
RxNorm normalized name: Aspalathus linearis leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linear multilevel treatment‐by‐covariate interaction
Trial: 32106837
Drug: Prophylactic quadrivalent
RxNorm normalized name: Fluarix Quadrivalent 2018-2019
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic quadrivalent HPV vaccine
Trial: 32758677
Drug: 100 mcg
RxNorm normalized name: Levo-T 100 MCG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mcg nebulized fentanyl
Trial: 34040400
Drug: Celecoxib (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib (100 mg twice daily)
Trial: 33797074
Drug: Chlorpromazine 12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorpromazine 12.5 mg
Trial: 33797074
Drug: Prochlorperazine 12.5
RxNorm normalized name: prochlorperazine 12.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prochlorperazine 12.5 mg
Trial: 35506164
Drug: MK-1654 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-1654 (100 mg i.m.)
Trial: 35506164
Drug: MK-1654 (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-1654 (300 mg i.m.)
Trial: 35506164
Drug: MK-1654 (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-1654 (300 mg i.v.)
Trial: 35506164
Drug: MK-1654 (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-1654 (1000 mg i.v.)
Trial: 33909354
Drug: Acupuncture for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture for regulating shen and strengthening spleen, applied to acupoints Baihui (GV 20), Yintang (GV 29), Tianshu (ST 25), Shangjuxu (ST 37), and Zusanli (ST 36), treatment given once every 2 days, 3 times a week for 6 weeks.
Trial: 33909354
Drug: Pinaverium bromide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pinaverium bromide, 50 mg orally, 3 times daily for 6 weeks.
Trial: 34346566
Drug: Complementary and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complementary and alternative medicine group
Trial: 35773693
Drug: Xing‐Nao Kai‐Qiao
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xing‐Nao Kai‐Qiao acupuncture therapy plus language training
Trial: 35773693
Drug: Sham‐acupoint acupuncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham‐acupoint acupuncture therapy plus language training
Trial: 33571957
Drug: CAF (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAF (5 mg·kg‐1 caffeine)
Trial: 32996442
Drug: Housing First
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Housing First (HF) program with Assertive Community Treatment team support
Trial: 32761191
Drug: Low Glycemic
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low Glycemic Index Therapy Diet (LGIT)
Trial: 32761191
Drug: Ketogenic Diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketogenic Diet (KD) vs Low Glycemic Index Therapy Diet (LGIT)
Trial: 35059305
Drug: Chatbot therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chatbot therapy (n = 41)
Trial: 34008856
Drug: Astragalus polysaccharide
RxNorm normalized name: Astragalus polysaccharides
DrugBank: Astragalus mongholicus root polysaccharides (DB17721)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Astragalus polysaccharide (APS) at concentrations of 40, 100, or 400 μg/mL
Trial: 34008856
Drug: FA-treated cells
RxNorm normalized name: trimethylsilyl treated diimethiconol-trimethylsiloxysilicate crosspolymer (45-55 WW)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FA-treated cells (FA group, 120 μmol/L)
Trial: 33050833
Drug: Naltrexone (mu-opioid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (mu-opioid blocker)
Trial: 32032997
Drug: Olive oil
RxNorm normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olive oil (52 mL/day)
Trial: 34814232
Drug: Black myrobalan
RxNorm normalized name: acid black 52
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Black myrobalan (500 mg capsules, six capsules per day for 4 weeks)
Trial: 32940679
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of the treadmill and electrical neuromuscular stimulation for 15 to 20 minutes each session
Trial: 37702442
Drug: Continuous antibiotic
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous antibiotic prophylaxis
Trial: 33289598
Drug: Control (not
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (not receiving continuous antibiotic prophylaxis as per model recommendation)
Trial: 34083231
Drug: Once‐every‐3‐weeks cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once‐every‐3‐weeks cisplatin at 100 mg/m2 for two cycles
Trial: 34083231
Drug: Once‐a‐week cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once‐a‐week cisplatin at 40 mg/m2 for six cycles
Trial: 32214299
Drug: Paramedian approach
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paramedian approach of lumbar epidural injection (LEI)
Trial: 32214299
Drug: Midline approach
RxNorm normalized name: amidoline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midline approach of lumbar epidural injection (LEI)
Trial: 32883724
Drug: Multicomponent intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multicomponent intervention to improve adherence to cardiac rehabilitation (CR) and cardiovascular medications.
Trial: 34569334
Drug: Intravenous injection
RxNorm normalized name: Meta Trace FDG, intravenous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of 2 g tranexamic acid (TXA) and local use of 1 g intraoperatively (Group B)
Trial: 34569334
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 2 g tranexamic acid (TXA) and 10 mg rivaroxaban qd treatment postoperatively (Group C)
Trial: 34569334
Drug: 0.9% NaCl
RxNorm normalized name: Trace Metals Additive in 0.9% NaCl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% NaCl solution intravenously (Group A)
Trial: 34380473
Drug: Piezo-surgery with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piezo-surgery with 8 mg dexamethasone
Trial: 35803172
Drug: Dual bronchodilator
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual bronchodilator therapy with umeclidinium bromide (UMEC)/vilanterol (VI)
Trial: 35803172
Drug: Monotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy with umeclidinium bromide (UMEC)
Trial: 35803172
Drug: Monotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy with salmeterol (SAL)
Trial: 34489263
Drug: Shorter, more
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shorter, more tolerable regimens of oral drugs
Trial: 32348699
Drug: short-term existential
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: short-term existential behavioural therapy (sEBT); 2 individual 1-h sessions
Trial: 34775948
Drug: Modified high-flow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified high-flow nasal cannula (HFNC) oxygen therapy
Trial: 32034697
Drug: Plasma endostatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma endostatin levels (≥ 84.22 ng/mL)
Trial: 32955200
Drug: AXA1665 14.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AXA1665 14.7 g t.i.d.
Trial: 36369133
Drug: Electroacupuncture and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroacupuncture and intradermal press needles (Acupuncture group, n=35)
Trial: 34670131
Drug: Extended-release naltrexone
RxNorm normalized name: bupropion / naltrexone Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release naltrexone injection (XR-NTX), n = 283
Trial: 35225510
Drug: Intravitreal antifungal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal antifungal agents and systemic therapy
Trial: 35225510
Drug: Antifungal stewardship
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antifungal stewardship
Trial: 32460239
Drug: Chocolate-flavored dairy
RxNorm normalized name: Beano Dairy Defense
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chocolate-flavored dairy milk recovery beverage (1.2 g/kg body mass carbohydrate and 0.4 g/kg body mass protein)
Trial: 38652999
Drug: Cenobamate 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cenobamate 400 mg/day
Trial: 35168142
Drug: Cenobamate 200
RxNorm normalized name: cenobamate 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cenobamate 200 mg/day and 400 mg/day with SCBs
Trial: 33788024
Drug: High-dose purified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose purified EPA (icosapent ethyl)
Trial: 33788024
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (statins)
Trial: 33734167
Drug: HP-3070 3.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HP-3070 3.8 mg/24 hours
Trial: 33734167
Drug: HP-3070 7.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HP-3070 7.6 mg/24 hours
Trial: 33734167
Drug: HP-3070 (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HP-3070 (daily application)
Trial: 32530717
Drug: Yoga-based physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yoga-based physical therapy (YPT)
Trial: 32989470
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid (5 mg intravenous injection) plus calcitriol (0.5 μg/day) and calcium carbonate (1000 mg/day)
Trial: 32989470
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (calcitriol 0.5 μg/day and calcium carbonate 1000 mg/day without ZOL)
Trial: 35642923
Drug: Parenteral vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral vitamin B12 (1000 µg IM for initial dose, followed by 3 doses on alternate days for <10 years or 5 doses for >10 years, then monthly 1000 µg IM)
Trial: 35642923
Drug: Oral vitamin
RxNorm normalized name: vitamin A Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vitamin B12 (1500 µg daily for 3 months, 500 µg for <2 years)
Trial: 36364801
Drug: WPH (ERD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WPH (ERD + 20 g/d WPH)
Trial: 36364801
Drug: WP (ERD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WP (ERD + 20 g/d WP)
Trial: 32761372
Drug: Aspirin 100
RxNorm normalized name: aspirin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 100 mg once a day (GA100)
Trial: 32761372
Drug: Aspirin 160
RxNorm normalized name: aspirin 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 160 mg once a day (GA160)
Trial: 32761372
Drug: Aspirin 100
RxNorm normalized name: aspirin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 100 mg twice a day (G2A100)
Trial: 32984232
Drug: Immersive aging
RxNorm normalized name: casein, Lactococcus lactis cultured, aged
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immersive aging simulation suit and medication review polypharmacy workshop
Trial: 32984232
Drug: Medication review
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication review polypharmacy workshop (control)
Trial: 32646482
Drug: myo-inositol and
RxNorm normalized name: myo-inositol
DrugBank: Inositol (DB13178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: myo-inositol and folic acid (4000 mg myo-inositol and 400 mcg folic acid daily)
Trial: 32646482
Drug: folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: folic acid alone (400 mcg folic acid daily)
Trial: 32450344
Drug: Tirofiban (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tirofiban (25 μg/Kg as bolus infusion, followed by 0.15 μg/Kg/min continuous infusion for 48 hours), acetylsalicylic acid (250 mg infusion and 75 mg daily for 30 days), clopidogrel (300 mg oral and 75 mg daily for 30 days), fondaparinux (2.5 mg/day subcutaneous for duration of hospital stay)
Trial: 32450344
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving prophylactic or therapeutic dose heparin
Trial: 32398324
Drug: Olaparib 300
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib 300 mg twice daily and durvalumab 1,500 mg intravenously every 4 weeks until disease progression, unacceptable toxicity, or withdrawal of consent.
Trial: 33862350
Drug: 5% pomegranate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% pomegranate peel extract solution used with a pulsating jet irrigator
Trial: 36431314
Drug: Non-surgical periodontal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-surgical periodontal therapy (TG)
Trial: 35206569
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (CFS) maintained their daily routines as normal
Trial: 33563509
Drug: Conservative rehabilitation
RxNorm normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative rehabilitation therapy only (control group)
Trial: 34429197
Drug: Fixed-dose combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination of rosuvastatin 2.5 mg and ezetimibe 10 mg (R2.5+E10)
Trial: 34429197
Drug: Ezetimibe 10
RxNorm normalized name: ezetimibe 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe 10 mg monotherapy (E10)
Trial: 34429197
Drug: Rosuvastatin 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 2.5 mg (R2.5)
Trial: 34429197
Drug: Rosuvastatin 5
RxNorm normalized name: rosuvastatin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 5 mg monotherapy (R5)
Trial: 32410652
Drug: Oral food
RxNorm normalized name: Nutritional Supplement Oral Food, Solid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral food challenge (OFC)
Trial: 32130661
Drug: Basal insulin-based
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Basal insulin-based treatment (insulin glargine plus OADs)
Trial: 32130661
Drug: Twice-daily premixed
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily premixed insulin (NovoLog® Mix 70/30)
Trial: 35505122
Drug: Aged garlic
RxNorm normalized name: Garlic 600 MG Oral Tablet [KYOLIC AGED GARLIC EXTRACT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aged garlic extract (AGE) 2.4 g
Trial: 32686262
Drug: Autologous skin
RxNorm normalized name: Autologous skin culture
DrugBank: Autologous skin culture (DB18524)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous skin cell suspension (ASCS) in combination with standard therapy
Trial: 33783059
Drug: Cognitive Remediation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Remediation (CR) plus Treatment as Usual (TAU)
Trial: 33902655
Drug: Online questionnaire
RxNorm normalized name: FILTER,SUCTION,INLINE #FHBF200S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Online questionnaire administration
Trial: 616952074
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of paracetamol 1000mg
Trial: 616952074
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of paracetamol 1000mg
Trial: 33969764
Drug: Paravertebral intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paravertebral intramuscular Ozone injection
Trial: 33969764
Drug: Caudal epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal epidural steroid-hyaluronidase injection